Literature DB >> 15328164

Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.

Jonathan W Friedberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328164     DOI： 10.1158/1078-0432.CCR-04-0922

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

Review 1.  Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Authors:  Manzurul A Sikder; Jonathan W Friedberg
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

2.  Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Authors:  Jonathan W Friedberg; Jennifer L Kelly; Donna Neuberg; Derick R Peterson; Jeffery L Kutok; Rabih Salloum; Thomas Brenn; David C Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G Rothberg; Jane Liesveld; Richard I Fisher; Robert Coffman; Tim Mosmann; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-06-10       Impact factor: 6.998

Review 3.  Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Authors:  Manzurul A Sikder; Jonathan W Friedberg
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

Review 4.  Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.

Authors:  Jonathan W Friedberg; Arnold S Freedman
Journal:  Curr Treat Options Oncol       Date:  2006-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.